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Abstract
The mouse pituitary gland secretes hormones that regulate many physiological
processes including growth, stress response, and reproduction. The canonical WNT
signaling pathway, activation of which results in nuclear accumulation of β-CATENIN and
transcription of target genes including LEF1, is crucial for proper development of the
pituitary gland. Pituitary progenitors that lack β-CATENIN at embryonic day of
development 8.5 (E8.5) cannot form three of the six cell types of the anterior pituitary
that produce growth hormone (GH), thyroid stimulating hormone (TSH), and prolactin
(PRL). Additionally, stimulating canonical WNT signaling through creation of
degradation-resistant β-CATENIN at E9.5 causes pituitary tumors and results in a
reduction in the number of GH and TSH secreting cells. However, if canonical WNT
signaling is stimulated in differentiating pituitary cells at E14.5, there is no loss of
hormone cell types or tumor formation, demonstrating that the timing of the signaling is
critical. Based on these results we chose to activate canonical WNT signaling at E11.5 in
pituitary progenitors by creating a degradation-resistant β-CATENIN using a Cre/loxP
strategy to excise a portion of β-CATENIN exon 3 necessary for normal degradation. We
found that activation of canonical WNT signaling at E11.5 resulted in hyperplastic
pituitaries, increased epithelial-like tissue, and complete loss of all hormone-producing
cell lineages. Our results demonstrate that proper regulation and timing of canonical
WNT signaling during pituitary development is critical for proper differentiation of
pituitary progenitors into hormone cell types.
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Introduction
The pituitary gland, referred to as the “master gland” of the body due to its
influence on other endocrine glands, regulates a host of physiological processes
including growth, metabolism, sexual development, and long-term stress response.
Connected to the hypothalamus by the infundibular stalk, the mouse pituitary is
comprised of the anterior, posterior, and intermediate lobes, each populated by a
unique group of hormone-producing cell types. The anterior pituitary’s somatotrophs,
thyrotrophs, corticotrophs, lactotrophs, and gonadotrophs respectively secrete growth
hormone (GH), thyroid-stimulating hormone (TSH), adrenocorticotrophic hormone
(ACTH), prolactin (PRL), and the gonadotrophic hormones, luteinizing hormone (LH) and
follicle-stimulating hormone (FSH). The posterior lobe, meanwhile, stores and secretes
antidiuretic hormone and oxytocin (both synthesized by the hypothalamus). In mice, the
intermediate lobe’s hormone cell types secrete melanocyte-stimulating hormone
(MSH). In humans, however, the intermediate lobe is rudimentary and reduced, and the
melanotrophs are mixed into the anterior lobe.

Pituitary disease
Due to the wide range of processes under the control of the pituitary, disruption
to normal pituitary function can cause a wide range of phenotypes. For example,
deficiency or absence of any of the hormone-producing cell types is characteristic of
hypopituitarism and can cause dwarfism in the absence of GH or adrenal insufficiency in
the absence of ACTH. A combination of GH deficiency with deficiency in any other
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hormone cell type constitutes diagnosis of combined pituitary hormone disease (CPHD),
a rare condition in humans most often caused by mutations in Prophet of Pit1 (PROP1),
the gene encoding a pituitary-specific transcription factor (Cohen & Radovick, 2002).
The physiological deficits observed in individuals with CPHD depend on which hormones
are absent, but can include short stature, fatigue, delayed puberty, infertility, and
intellectual disability in rare cases.
Conversely, problems can arise due to oversecretion of pituitary hormones.
Adenomas are benign, slow-growing pituitary tumors that secrete excess hormones,
causing a variety of physiological effects dependent on the particular hormone secreted
(Sharif-Alhoseini & Rahimi-Movaghar, 2012). Adenomas secreting GH, for instance, can
result in acromegaly or gigantism. Additionally, an adenoma secreting excess ACTH can
result in Cushing’s Disease, characterized by weight gain, impaired immune response,
and fat deposits around the neck or face.

Early pituitary development
During embryonic development, the pituitary gland is produced from two
ectodermal tissues: the oral ectoderm and the neural ectoderm. At approximately
halfway through mouse gestation on embryonic day of development 9.5 (E9.5), cells of
the anterior pituitary placode in the oral ectoderm invaginate to form Rathke’s pouch,
the precursor to the anterior and intermediate lobes (Scully and Rosenfield, 2002).
Formation of Rathke’s pouch creates a lumen surrounded by cells maintaining an
epithelial structure. The posterior pituitary forms from the ventral diencephalon, which
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evaginates around E10, forming an infundibulum, and directly contacts dorsal regions of
Rathke’s pouch. Proteins expressed in this infundibular region act as a signaling and
organizing center that is necessary for the development of Rathke’s pouch (Scully and
Rosenfield, 2002). Figure 1 shows a basic timeline of pituitary formation from the
invagination of the oral ectoderm into Rathke’s pouch and initial formation of the
anterior lobe between E10.5 to E14.5.

Extrinsic signaling required for pituitary organogenesis and development
Initial patterning and formation of Rathke’s pouch is mediated by expression of
extrinsic signaling molecules from the ventral diencephalon and oral ectoderm at E9.
Signals from the ventral diencephalon include members of the bone morphogenetic
protein and fibroblast growth factor families (BMP4, FGF8, and FGF10). Meanwhile,
sonic hedgehog (SHH) is expressed in the ventral diencephalon in a domain adjacent to
BMP4 and the FGFs and also in the oral ectoderm, except in region destined to become
Rathke’s pouch (Treier et al., 1998). Disruption of this delicate coordination of signaling
factors inhibits genesis and growth of Rathke’s pouch. For instance, loss of BMP4 causes
failure of Rathke’s pouch formation. Additionally, sustained overexpression of FGF8
within the developing pituitary causes excess proliferation, enlarged pituitaries, and
absence of cell lineages including gonadotropes, thyrotropes, somatotropes, and
lactotropes (Treier et al., 1998).

Transcription factors required for pituitary organogenesis and development
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Apart from signaling molecules, pituitary development is also controlled by the
presence of transcription factors in Rathke’s pouch. These transcription factors are
particularly important for mediating the transition from a proliferating progenitor state
to the mature hormone-producing cell types of the anterior lobe. PITX1 and PITX2 are
expressed in the oral ectoderm before E8.5 and play roles in limb development as well
as in the expansion and differentiation of the pituitary progenitor pool shortly after
Rathke’s pouch formation (Zhu & Rosenfield, 2004). Notably, the homeobox protein
HESX1, expressed beginning at E8.5, is crucial for invagination of the oral ectoderm and
acts as a general transcriptional repressor proposed to restrict FGF expression such that
only a single invagination of Rathke’s pouch occurs (Rizzoti and Lovell-Badge, 2005).
Between E11.5 and E13.5, anterior lobe progenitors exit the cell cycle and begin to
differentiate, all while leaving the epithelium of the pituitary lumen and entering the
developing anterior lobe (Davis et al., 2011). Transcription factors including Prophet of
Pit1 (PROP1), POU domain, class 1, transcription factor 1 (POUF1), steroidogenic factor 1
(SF1), and T-box transcription factor 19 (TBX19) modulate this transition from
progenitor to differentiated cell type. Beginning at E10.5, PROP1, the first pituitaryspecific transcription factor, begins to be expressed. Importantly, all hormone-producing
cell types from the intermediate and anterior lobes derive from PROP1-positive
progenitor cells, demonstrating that there is a common pool of progenitor cells for all
hormone cell types (Davis et al., 2016). Additionally, PROP1 silences HESX1 expression
and directly activates POUF1, the signature transcription factor that gives rise to the cell
lineage that will produce somatotrophs, lactotrophs, and thyrotrophs (Olson et al.,
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2006). Mutations in PROP1 and POU1F1 are implicated in human combined pituitary
hormone deficiency (CPHD), a disorder characterized by deficiencies in GH and at least
one other hormone. Mutations in PROP1 are the most common genetic cause of CPHD,
accounting for approximately 50 percent of all cases of CPHD with over 15 distinct
mutations identified across numerous individuals, pedigrees, and countries of origin
(Deladoëy et. al, 1999). Likewise, POU1F1 mutations have been described in 46 patients
from 34 families from a wide range of countries of origin; all described cases are similar
phenotypically in their deficiency in GH, TSH, and PRL (Cohen & Radovick, 2002).
At the same time POU1F1 becomes active in the somatotrophs, lactotrophs, and
thyrotroph lineages, transcription factors SF1 and TBX19 likewise become active in their
respective subset of PROP1-positive pituitary progenitors. SF1 regulates transcription of
genes related to sexual development and characterizes the gonadotroph lineage that
secretes FSH and LH (Ingraham et al., 1994). Additionally, TBX19 is expressed in the
pituitary pro-opiomelanocortin cell lineage that produces corticotrophs and
melanocyte-stimulating hormone (MSH) – producing melanotrophs (Lamolet et al.,
2001). Mutations in these lineage markers of differentiation can result in loss of the
hormone-producing cell type lineage associated with each transcription factor
(Ingraham et al., 1994; Lamolet et al., 2001). Figure 2 shows a timeline of pituitary
development, emphasizing the temporal expression of specific transcription factors in
the differentiation of pituitary progenitors to hormone producing cell types.

Canonical WNT signaling and pituitary development

7

The WNT signaling pathway is crucial for numerous developmental processes
during embryogenesis and adult tissues, with effects ranging from cell proliferation to
differentiation (Logan & Nusse, 2004). Non-canonical WNT signaling pathways function
to regulate the cytoskeleton and to control intracellular calcium levels. Canonical WNT
signaling is associated with the protein β-CATENIN, which forms complexes with
transcription factors in the lymphoid enhancer binding factor (LEF) and TCF DNA binding
protein families to regulate transcription. When a WNT protein binds to its Frizzled
receptor, the signal is transduced to intracellular proteins including the protein kinase
GSK-3, APC, AXIN, and β-CATENIN (Logan & Nusse, 2004). Normally, cytoplasmic βCATENIN levels are kept low by degradation through a GSK-3/APC/AXIN degradation
complex. When a cell binds a WNT ligand, the degradation complex is inhibited and βCATENIN is allowed to accumulate, translocate to the nucleus, and bind its
transcriptional targets in combination with LEF/TCF cofactors. Figure 3 shows a
schematic of the canonical WNT pathway in cells. In the mouse, knockout of various
WNT family ligands produces phenotypes ranging from truncated limbs to infertility to
reduction in neural precursors to gastrulation defects; these defects are all rooted in
reduced cell proliferation, indicating the importance of WNT signaling in regulating cell
proliferation (Logan & Nusse, 2004). Conversely, mutations that activate WNT signaling
have been linked to cancer. Mutations in APC and CTNNB1 (the gene encoding βCATENIN protein) are known to cause approximately 90% of all sporadic colorectal
cancers (Giles et al., 2003). Other activating mutations in WNT signaling are linked to
cancers including gastrointestinal tumors outside the large intestine, melanomas, and
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pilomatricomas, a benign skin tumor derived from the hair matrix (Giles et al., 2003). In
most cases, activating CTNNB1 mutations occur in or around exon 3, affecting the
phosphorylation sites GSK uses to degrade β-CATENIN, allowing the transcription factor
to accumulate unchecked in the nucleus (Giles et al., 2003).

Role of β-CATENIN in pituitary development and differentiation of pituitary progenitors
Previous studies have sought to understand how the timing of WNT signaling
and β-CATENIN activity is important for pituitary development. Conditional knockout of
β-CATENIN using Pitx1-Cre (at approximately E9.5) results in the loss of POU1F1
expression and the POU1F1 lineage, indicating that β-CATENIN, together with PROP1, is
necessary to activate Pou1f1 expression (Olson et al., 2006). Indeed, β-CATENIN and
PROP1 form a complex together through interactions of the C-terminal 60 amino acid
domain of PROP1 and the full-length β-CATENIN (Olson et al., 2006). While β-CATENIN
assists in activating Pou1f1 expression, it has no role in the maintenance of Pou1f1
expression later in development; knockout of β-CATENIN later at E13.5 in the POU1F1
lineage using Pou1f1-Cre causes no phenotypic change. Additionally, β-CATENIN,
associated in a complex with PROP1, likewise assists in PROP1’s crucial role of repressing
Hesx1 (Olson et al., 2006). Premature expression of β-catenin resulted in absence of
Hesx1 expression at E9.5 and lack of a pituitary gland at E13.5. Further, chromatin
immunoprecipation in E12.5 pituitaries revealed presence of both PROP1 and βCATENIN in Hesx1 gene regulatory regions (Olson et al., 2006). Together, these results
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confirm β-CANENIN’s crucial role in activating and silencing gene expression during
pituitary development.
To understand the effect of activating canonical WNT signaling during
development, researchers have created a degradation-resistant β-CATENIN through the
use of a Cre-lox strategy which, upon the expression of CRE, excises a portion of exon 3
crucial for GSK-mediated degradation, similar to the mutations observed in human
cancers. To examine the effect of ectopic WNT signaling during pituitary development,
one experiment used a Hesx1-Cre recombinase to activate canonical WNT signaling in
Rathke’s pouch progenitors expressing HESX1 (Gaston-Massuet et al., 2011).
Surprisingly in these mutant mice, β-CATENIN activation was localized to small foci of
Rathke’s pouch progenitors instead of demonstrating widespread expression in every
Hesx1-positive cell. Additionally, transcription of Lef1, a transcriptional partner of βCATENIN that is also transcriptionally activated by canonical WNT signaling, increased
and was likewise organized into discrete foci. Further, post-mortem examination of mice
expressing the activated β-CATENIN revealed they developed pituitary tumors
(adamantinomatous craniopharyngioma [ACP]) and had reduced numbers of
somatotrophs and thyrotrophs. Since Pou1f1 expression is crucial for further
differentiation of cells into somatotrophs and thyrotrophs, the loss of Pou1f1 in this
experiment explains the lack of differentiation into mature hormone-producing cells in
the POU1F1 lineage. This same report also described activation of β-CATENIN at later
time points in committed Pou1f1+ cells or terminally differentiated GH-producing and
PRL-producing cells, which resulted in the development of normal adult pituitaries
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without ACP (Gaston-Massuet et al., 2011). Thus, while activating WNT signaling with
Hesx1-Cre (at approximately E9.5) causes a recognizable ACP phenotype, activating WNT
signaling later in development in lineage-committed progenitors or mature hormoneproducing cells is not tumorigenic and results in normal pituitary structure and function
(Gaston-Massuet et al., 2011). These results indicate that proper timing of canonical
WNT signaling plays a role in ACP tumorgenesis and the differentiation of pituitary
progenitors to hormone-producing cell types in mice. In human cases of ACP, over 75%
(n=121) exhibit mutations in exon 3 of the CTTNB1 gene encoding β-CATENIN (Goschzik
et al., 2017). These results, in combination with previous mouse studies, show that
canonical WNT signaling plays a critical role in development and differentiation of
pituitary progenitors through β-CATENIN’s silencing of Hesx1 expression and activation
of Pou1f1 expression, but some questions still remain. As previously described, pituitary
progenitors are sensitive to β-CATENIN activated at E9.5 using a Hesx1-Cre but not later
in development at E13.5 using a Pou1f1-Cre. However, activation of canonical WNT
signaling has not been studied during a critical window of pituitary development (E11.5)
after Rathke’s pouch has formed but before the distinct hormone lineages have been
established.
The work described here seeks to evaluate the effect of activating canonical
WNT signaling on the development and differentiation of the pituitary using a Prop1
driven CRE recombinase. Prop1 is expressed exclusively in the pituitary at a later time
point (approximately E11.5) than Pitx1 and Hesx1, but earlier than Pou1f1. These
experiments will provide insights into the effects of activating canonical WNT signaling
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at an intermediate time point after Rathke’s pouch and the pituitary stem cell
population have been established, but before the POU1F1, TBX19, and SF1 progenitor
lineages have been established. We predict that activating β-CATENIN at this
intermediate time point will result in a less severe phenotype than activating earlier in
development with the Hesx1-Cre, but will produce a more severe phenotype than
activating β-CATENIN in committed progenitors as previously described with the Pou1f1Cre.

Methods
Cre recombinase and mouse line
To generate the tissue-specific activation of canonical WNT signaling, we
implemented a Cre-loxP strategy using a promoter from Prop1, a transcription factor
expressed exclusively in the pituitary progenitors, to drive the expression of CRE in only
the pituitary progenitors (Davis et al., 2016). CRE, a recombinase enzyme derived from
the P1 bacteriophage, recognizes a 34-base pair sequence called loxP sites and functions
to bring two loxP sites together for recombination (Kos, 2004). Depending on the
location and orientation of loxP sites, a variety of genetic alterations can be
accomplished. Most important for this project is arranging the loxP sites so that they are
flanking the target gene with two loxP sites arranged in the same orientation. This
arrangement, known as a “floxed” allele, results in excision of the target sequence (Kos,
2004). In the case of the β-catenin, the loxP sites are arranged around exon 3 such that
CRE recombinase deletes exon 3. The β-CATENIN protein produced from the
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recombined β-catenin allele is functional, but lacks the amino acids encoded by exon 3.
A portion of exon 3, containing the region allowing for phosphorylation and degradation
by AXIN, APC, and GSK3, is therefore excised in tissues expressing the Prop1 controlled
CRE recombinase. Excising the region responsible for degradation results in a
degradation-resistant β-CATENIN, mimicking the β-catenin mutations found in human
ACP.
To generate a mouse line with pituitary specific canonical WNT signaling
activation, two mouse lines must be crossed: one mouse strain containing homozygous
floxed alleles of β-catenin (β-cateninGOF/GOF) and one strain expressing the hemizygous
CRE recombinase under control of a Prop1 promoter (Prop1-Cre). This cross results in
wild type embryos that do not have the Prop1-Cre and are heterozygous for the GOF βcatenin allele and mutant embryos that are Prop1-Cre/+; β-CATENINGOF/+. The initiation
of embryonic development was determined by the observation of a copulation plug.
Noon of the day the plug was observed was established at E0.5 as previously described
(Osmundsen et al., 2017).

H&E and Immunohistochemistry
Hematoxylin and eosin (H&E) staining was performed as previously described
(Cardiff et al., 2014). Mouse embryos collected at a variety of time points were fixed in
4% paraformaldehyde overnight at 4 C, followed by washes in phosphate-buffered
saline (PBS), dehydration in a graded ethanol series, and perfusion with paraffin to
generate paraffin embedded embryos for sectioning at 6 μm as previously described
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(Osmundsen et al., 2017). Slides used for immunohistochemistry were prepared for
immunostaining with sequential baths in xylene to remove paraffin and then hydrated
with solutions of 100% and 95% ethanol, followed by PBS. Immunohistochemistry was
performed as previously reported (Osmundsen et al., 2017). Table 1 shows antibodies
used, dilution, species in which the antibodies were generated, and amplification for
each experiment. For each immunohistochemistry protocol, slides were treated with
primary antibody at 4oC overnight. Antibodies requiring a directly conjugated secondary
antibody are treated with a secondary antibody with a fluorescent tag and mounted
with fluorescent mounting media for image capture. Primary antibodies requiring
additional amplification for detection were treated with a biotinylated secondary
antibody and then detected using either a biotin-binding streptavidin covalently
attached to a florescent label or are further amplified using a horseradish peroxidaseconjugated streptavidin, which reacts with a tyramide signal amplification reagent (TSA),
producing a florescent product. All slides were counterstained with 4',6-diamidino-2phenylindole (DAPI).
Notably, two different antibodies recognizing β-CATENIN were used in these
experiments. The mouse anti-β-CATENIN primary antibody was used when performing
double immunostaining in order to prevent cross-reactivity with other primary
antibodies. In addition, a directly conjugated secondary antibody was used to
discriminate between areas of low versus high β-CATENIN accumulation. Only areas
with high β-CATENIN accumulation could be detected using the mouse anti-β-CATENIN
in combination with a directly conjugated secondary antibody.
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Apoptosis was detected using DeadEnd Fluorometric
deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) System
(Promega, Madison, WI), according to the manufacturer’s protocol.

Epithelial Area Quantification
Using ImageJ, we calculated the average epithelial area of five sagittal pituitary
sections for four wild type and four mutant embryos at E14.5. The five pituitary sections
were selected in order to capture epithelial area quantifications across the entire width
of the pituitary. Tissues counted as epithelium was determined by morphology of the
tissue. The area calculations for the five pituitary sections for each embryo were
averaged together to create an average epithelial area for each of the four wild type and
four mutant pituitaries. Epithelial area values for wild type and mutant pituitaries were
compared using a Two-Sample t-Test Assuming Unequal Variances.

Results
Prop1-Cre/+; β-CATENINGOF/+ mutants have hyperplastic pituitaries and increased
epithelial tissue
To reveal morphological changes to the pituitary caused by activating canonical
WNT signaling in pituitary progenitors, we performed H&E staining on histological
pituitary sections. While H&E at E12.5 revealed no significant difference in morphology
(Fig. 4 a-b), H&E at E14.5 and E16.5 revealed mutant pituitaries to be hyperplastic and
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dysmorphic (Fig. 4 c-f). Although Prop1-Cre is active starting at E11.5, morphological
changes are not seen in the pituitary until E14.5 at the earliest.
Mutant pituitaries appeared to exhibit a larger amount of epithelial tissues,
confirmed by comparing area quantification of wild type and mutant embryos (Fig. 4i).
Immunostaining for cytokeratin8, a marker of simple epithelium found in Rathke’s
pouch, revealed a marked increase in epithelial cells in the mutant pituitaries (Fig. 4 gh).

Accumulation of β-CATENIN and canonical WNT signaling activation occurs in a subset of
PROP1+ pituitary progenitors
To determine when β-CATENIN activation and accumulation occurs after Prop1Cre recombination, immunostaining for β-CATENIN was performed at E12.5, E14.5, and
E16.5. Immunostaining for β-CATENIN notably revealed that β-CATENIN was localized
into foci throughout the anterior pituitary (Fig. 5). At E12.5, small clusters of β-CATENIN
began forming in the epithelium of the pituitary (Fig. 5 a-b). At E14.5 and E16.5, a large
proportion of the pituitary exhibited clusters of activated β-CATENIN (Fig. 5 c-f).
However, not every cell or even every epithelial-like cell expressed high levels of βCATENIN even though these cells express PROP1, the driver of the CRE recombinase
which generates the degradation-resistant β-CATENIN (Fig. 6). Additionally, double
immunostaining for PROP1 and β-CATENIN (marked by directly conjugated β-CATENIN
as described earlier to detect only high expression of β-CATENIN) revealed that PROP1 is
only expressed in cells that do not have high levels of β-CATENIN (Fig. 6 c-e). These
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results indicate that not every PROP1+ pituitary progenitor express the activated βCATENIN and suggests, together with similar findings in Hesx1-Cre mutants where βCATENIN is localized to small foci, some mechanism that can potentially limit
accumulation of β-CATENIN in some pituitary progenitors.
To ensure canonical WNT signaling was stimulated by the activated β-CATENIN
protein, we performed immunostaining for LEF1, which forms a complex with βCATENIN and is also transcriptionally activated by canonical WNT signaling. Staining at
E16.5 revealed that LEF1 is organized into discrete clusters similar to β-CATENIN and
that LEF1 appears in discrete foci as early as E12.5, a time point where LEF1 is not
normally expressed (Fig. 7 a-d). Double immunostaining for β-CATENIN using the mouse
anti-β-CATENIN antibody with a directly conjugated secondary antibody (to detect only
regions of high β-CATENIN expression) and LEF1 at E14.5 revealed that LEF1 is localized
to regions of high β-CATENIN expression, indicating that canonical WNT signaling is
active, leading to the transcription of LEF1 and other targets of β-CATENIN (Fig. 7 e-f).

Cells with high levels of activated β-CATENIN do not express pituitary stem cell markers
or markers of proliferation
In order to better characterize the high- β-CATENIN clusters formed in Prop1Cre/+; β-CATENINGOF/+ mutant pituitaries, we performed immunostaining for SOX2,
SOX9, Ki67, and CYCLIN D2, markers of stemness and proliferation previously studied in
relation to the ACP phenotype (Gaston-Massuet et al., 2011) (Fig. 8). While some cells
with epithelial-like morphology in mutant pituitaries express SOX2 or SOX9, cells with
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high levels of β-CATENIN (marked by directly conjugated β-CATENIN as described
earlier) failed to express SOX2 or SOX9, indicating they are not pituitary progenitor cells
(Fig. 8 b & d). Likewise, regions of high β-CATENIN expression did not express the
markers of proliferation Ki67 and CYCLIN D2, indicating they are in a quiescent, nonproliferative state (Fig. 8 f & h). Further, little to no cells in the mutant pituitaries are
apoptotic, indicating that activating canonical WNT signaling does not result in increased
cell death (Fig. 8 i-j).

Prop1-Cre/+; β-CATENINGOF/+ pituitaries do not express lineage markers and fail to
produce hormones
To understand how activating β-CATENIN in pituitary progenitors affects the
differentiation from a progenitor state into hormone-producing cell types, we
performed immunostaining at E16.5 for POU1F1, SF1, and TBX19, markers of the three
distinct cell lineages that populate the mature anterior pituitary. Expression of the
lineage markers were completely absent in the Prop1-Cre/+; β-CATENINGOF/+ pituitaries,
indicating differentiation has been severely affected by stimulating canonical WNT
signaling (Fig. 9 a-f). Since the lineage markers are required for terminal differentiation
into hormone-producing cells, one would predict the absence of hormones in the
mature pituitary. Immunostaining for hormone markers at E18.5 revealed the absence
of GH, TSH, LH, and ACTH (Fig. 10 a-h).
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Discussion
In this study, we show that activation of canonical WNT signaling in the mouse
pituitary progenitors inhibits differentiation of pituitary progenitors into hormone
producing cell types and causes excess epithelial structures beginning at E14.5. Prop1Cre/+; β-CATENINGOF/+ mutants do not express POU1F1, TBX19, or SF1, markers of the
distinct cell lineages that give rise to all hormone-producing cell types of the anterior
pituitary and additionally fail to express any hormones, indicating that activation of
canonical WNT signaling can inhibit progenitor cell differentiation.
Our results, combined with the wider body of research, indicate that the timing
of canonical WNT signaling activation is crucial for pituitary gland development. One
previous study, using a Hesx1 driven CRE in combination with a β-CATENIN gain-offunction allele to achieve canonical WNT signaling activation at E8.5, resulted in a
phenotype similar to human ACP, a pituitary tumor derived from undifferentiated
progenitor cells (Gaston-Massuet et al., 2011). Activation of canonical WNT signaling at
this time point also inhibited the expression of Pou1f1 and resulted in a decrease in the
number of somatotrophs and thyrotrophs (Gaston-Massuet et al., 2011). ACTH and CGA
(marking LH, FSH, and TSH, heterodimers which share a common alpha subunit) were
still expressed, demonstrating that activation of canonical WNT signaling does not result
in a complete loss of hormone cell types. However, activating canonical WNT signaling
later in development around E14.5 in committed progenitors using a Pou1f1 driven CRE
results in a normal pituitary phenotype with no observable effect on differentiation. The
data presented here reflect the activation of canonical WNT signaling at an intermediate
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time point using a Prop1 driven CRE, active beginning at E11.5. Somewhat unexpectedly,
activating canonical WNT signaling at this intermediate time point causes a more severe
phenotype than activating at E8.5, using the Hesx1-Cre. Our manipulation resulted in
the complete loss of the cell lineages that give rise to all hormone-producing cell types
in the anterior pituitary and resulted in gross structural defects in the mutant pituitaries.
Similarly to the Hesx1-Cre study, activating canonical WNT signaling resulted in
the accumulation of β-CATENIN in a subset of cells in the pituitary. However, the high-βCATENIN regions in our study where markedly different from the ACP phenotype seen
previously (Gaston-Massuet et al., 2011). ACP regions in the Hesx1-Cre study express
SOX2 and CYCLIND2 while cells on the periphery of the tumors express SOX9 and Ki67.
In this study, areas outside of the high-β-CATENIN regions express all of these markers,
indicating that they are pituitary progenitors; however, high-β-CATENIN regions do not
express SOX2, SOX9, Ki67, or CYCLIND2, indicating that later timing of canonical WNT
signaling activation shifts the pituitary progenitors away from a pituitary identity. While
Prop1-Cre/+; β-CATENINGOF/+ embryos do not express markers of ACP seen previously,
our phenotype is similar in ways to the tumors created when activating β-CATENIN in
Sox2+ cells using an tomoxifen-indu tomoxifin cible CRE (Andoniadou et al., 2013). In
particular, this group found nuclear accumulation of β-CATENIN in foci surrounded by
cells exhibiting normal β-CATENIN accumulation. Additionally, these tumors were
undifferentiated, lacking POU1F1 and SOX9 in the foci and were quiescent, proven by a
lack of Ki67 in the foci (Andoniadou et al., 2013). Together, these results indicate that
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activation of canonical WNT signaling during pituitary development has tumorigenic
potential.
In addition to the more severe disruption of differentiation of progenitor cells,
activation of canonical WNT signaling at E11.5 with a Prop1-Cre results in a significant
increase in epithelial area, a phenotype not seen when activating canonical WNT
signaling earlier in development at E9.5. This increase in epithelial cells indicates that
activation of canonical WNT may play a role in inhibiting the transition of the pituitary
progenitor from an epithelial morphology to the more mature epithelioid structure that
characterizes the parenchyma of the adult anterior pituitary.
Our results also demonstrate a previously unreported result of increased
canonical WNT signaling – the repression of Prop1. In this study, areas with high βCATENIN fail to express PROP1, a marker of pituitary progenitors, suggesting a dual role
for β-CATENIN in relation to PROP1. PROP1 and β-CATENIN form a complex that both
represses Hesx1 and activates Pou1f1, but our results indicate that sufficiently high
levels of β-CATENIN can also inhibit the expression of Prop1. Combined with the
absence of pituitary stem cell markers, SOX2 and SOX9, this result also demonstrates
that Prop1-Cre+ cells are susceptible to high levels of canonical WNT signaling, which can
shift these cells away from a pituitary identity.
These results help to show the effect that presence and timing of β-CATENIN and
canonical WNT signaling have on the development of the pituitary and differentiation of
progenitors to hormone cell-types. Conditional knockout of β-CATENIN at E9.5 results in
the loss of Pou1f1, revealing the key role that β-CATENIN plays in concert with PROP1
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(Olson et al., 2006). Additionally, activation of β-CATENIN at various time points disrupts
normal development and differentiation of the pituitary. It has been previously shown
that activating canonical WNT signaling in Sox2+ progenitors or progenitors at E9.5
disrupt differentiation and are tumorigenic but that activating canonical WNT signaling
at E13.5 when hormone lineages have been established has no significant effect (Olson
et al., 2006). Our results prove that pituitary progenitors are still sensitive to activation
of canonical WNT signaling and that increased levels of β-CATENIN cause catastrophic
disruptions to pituitary development, resulting in the loss of all hormone cell types and
halting the transition from epithelial morphology to the mature morphology
characteristic of the adult pituitary parenchyma.
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Figure 1. Basic timeline of pituitary development from Rathke’s pouch formation (left)
at E10 to E14.5 where lobes of the pituitary are distinct (right).

Figure 3. Timeline of pituitary development from E8.5 to E17.5, showing the
temporal nature of transcription factor expression required for progression from
a progenitor state to mature hormone-producing cell type.
Figure 2.
Schematic of the
Canonical WNT
signaling pathway
showing the
degradation of βCATENIN in cells
lacking WNT (left)
and β-CATENIN
accumulation in
cells where a WNT
ligand has bound
the Frizzled
receptor.

25

Target protein
B-catenin
B-catenin
ACTH
Cyclin D2
Cytokeratin 8
GH
Ki67
Lef1
LH
Pou1f1
Prop1
Sf1
Sox2
Sox9
Tbx19
TSH

Dilution
1:100
1:1000
1:150
1:200
1:50-1:100
1:100
1:200
1:500
1:50
1:500
1:100
1:250
1:200
1:100
1:200
1:100

Amplification
Directly Conjugated Secondary
Strep
Directly Conjugated Secondary
TSA
TSA
Directly Conjugated Secondary
Directly Conjugated Secondary
TSA
Directly Conjugated Secondary
Directly Conjugated Secondary
TSA
TSA
TSA
Strep
Directly Conjugated Secondary
Directly Conjugated Secondary

Antibody animal background
Mouse
Rabbit
Rabbit
Rabbit
Rabbit
Monkey
Rabbit
Goat
Guinea Pig
Rabbit
Guinea Pig
Mouse
Rabbit
Rabbit
Rabbit
Guinea Pig

Table 1. Table of antibodies used including dilution, amplification level, and species in which the
antibody was raised.

Figure 4. Histological sections of
wild type and mutant mouse
pituitary stained with
hemotoxilin and eosin at E12.5
(a-b), E14.5 (c-d), and E16.5 (e-f)
time points. Beginning at E14.5,
gross differences in morphology
exist between wild type and
mutant pituitaries.
Immunostaining at E16.5 of
pituitaries with antibodies for
Cytokeratin 8 (pink), an indicator
of simple epithelium (g-h).
Below, epithelial area
quantification of wild type and
Prop1-cre; β-catenin GOF/+
pituitaries, measured using
ImageJ (i).

Amount of Epithelial Area

Epithelial area (mm2)

(i)
150
100
50
0

Normal Control

26 β-cateninGOF/
Prop1-cre;
+

Figure 5. Histological sections of wild type and mutant mouse pituitary marked with antibody specific for β-catenin
at E12.5 (a-b), E14.5 (c-d), and E16.5 (e-f). At E12.5, localization of β-catenin begins (white arrows) and localization is
prominent at E14.5 and E16.5
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Figure 6. Double immunostain for PROP1
and β-CATENIN in wild type (a) and
mutant pituitaries (b). Area contained by
the white box (b) is magnified for further
examination in panels c-e. PROP1 (d) is
only expressed in regions with low
expression of β-CATENIN and is absent in
high β-CATENIN regions (c). (e) shows a
double immunostain for PROP1 (red) and
β-CATENIN (green).
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Figure 7. Immunostaining of histological sections of wild type and mutant pituitary with an
antibody specific for LEF1 (a-b), indicating stimulation of Canonical WNT signaling at E16.5.
Immunostain for LEF1 at E12.5 (c-d) showing localization of LEF1 in mutant pituitaries (white
arrows).
Double immunostaining for β-catenin and LEF1 at E14.5 and E16.5 in mutant pituitaries,
demonstrating localization of LEF1 in high β-catenin regions (e-f).
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Figure 8. Immunostaining of histological sections of wild type and mutant pituitaries
for combination of β-catenin and SOX2 (a-b), SOX9 (c-d), Ki67 (e-f), or CYCLIN D2 (g-h)
as indicated. Region surrounded by yellow indicate high β-catenin regions that fail to
express SOX2, SOX9, Ki67, or CYCLIN D2, respectively. TUNEL was performed at E14.5
on wild type and mutant pituitaries to access presence of apoptosis (i-j).
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Figure 9. Immunostaining of
sections of wild type and
mutant pituitaries with
antibodies specific for
markers of cell lineages
POU1F1 (a-b), SF1 (c-d), and
TBX19 (e-f) at E16.5
revealing the complete
absence of all cell lineage
markers in mutant
pituitaries.

Figure 10. Immunostaining of sections of wild
type and mutant pituitaries at E18.5 with
antibodies specific for hormones GH (a-b), TSH
(c-d), ACTH (e-f), and LH (g-h). In mutant
pituitaries at E18.5, there is a complete loss of
all hormones of the anterior pituitary.
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